Treatment News : Dolutegravir Appears Superior to Raltegravir Among HIV Salvage Patients

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » March 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


March 11, 2013

Dolutegravir Appears Superior to Raltegravir Among HIV Salvage Patients

CROI 2013Interim 24-week results from a Phase III study comparing the investigatory dolutegravir to raltegravir among HIV-positive individuals who have experienced treatment failure suggest that dolutegravir is superior at suppressing virus. ViiV Healthcare announced these midway results from their 48-week, double-blind, double-dummy Phase III SAILING study at the 20th annual Conference of Retroviruses and Opportunistic Infections (CROI) in Atlanta.  

At the outset, the study’s 715 participants had resistance to at least two classes of antiretrovirals (ARVs). They also had replicating virus, a median baseline viral load of 63,000 and a median baseline CD4 count of 200. The participants were divided evenly into two study groups: One received once-daily dolutegravir and the other twice-daily raltegravir, both with a background regimen of no more than two other ARVs that the investigators selected.

At week 24 of the study, 79 percent of those taking dolutegravir achieved a suppressed viral load, compared with 70 percent of those on raltegravir. This difference was statistically significant, meaning that it was too great to have occurred by chance. At the same point, 15 percent of those on dolutegravir and 24 percent of those taking raltegravir had a virologic nonresponse. Two of those on the dolutegravir regimen failed therapy, compared with 10 of those taking raltegravir.

The tolerability of the two drugs was about even. At the 24-week mark, 2 percent of the participants taking dolutegravir discontinued because of adverse events, compared with 4 percent of those on raltegravir. Drug-related adverse events occurred in 20 percent of those on dolutegravir and 23 percent of those taking raltegravir. The most common adverse events were diarrhea and upper respiratory tract infection.

To read the ViiV release, click here.

To read the aidsmap story, click here.

To read the conference abstract, click here.

Search: dolutegravir, raltegravir, HIV, salvage, phase III, SAILING, 20th annual Conference of Retroviruses and Opportunistic Infections, CROI.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.